Skip to main
IONS
IONS logo

Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharma (IONS) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 31%
Buy 31%
Hold 31%
Sell 4%
Strong Sell 4%

Bulls say

Ionis Pharmaceuticals demonstrates a positive outlook due to its robust pipeline of novel drugs and strong financial performance. The company's higher than anticipated R&D revenue of $141 million, coupled with the successful launch of Wainua generating $42 million in sales and $10 million in royalty revenue, indicates a strong growth trajectory. Additionally, Ionis's favorable payer dynamics, which allow the majority of patients to incur $0 out-of-pocket costs, and the untapped market, with only 20% of patients currently treated, further enhance the company's growth potential in the therapeutic areas it targets.

Bears say

Ionis Pharmaceuticals has faced significant financial challenges, with substantial losses and an anticipated lack of profitability for several years, leading to a negative outlook for the stock. The company's guidance indicates a revenue range for 2025 that falls short of consensus estimates, primarily due to a projected decline in R&D revenue, despite expectations for an increase in commercial revenue. Furthermore, competitive pressures, particularly regarding market share erosion of Spinraza, and uncertain outcomes linked to other product performances, contribute to the risks surrounding the company's financial stability and growth potential.

Ionis Pharma (IONS) has been analyzed by 26 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 4% advise Selling, and 4% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ionis Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ionis Pharma (IONS) Forecast

Analysts have given Ionis Pharma (IONS) a Buy based on their latest research and market trends.

According to 26 analysts, Ionis Pharma (IONS) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ionis Pharma (IONS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.